Affordable Access

Enhancing sensitivity to platinum-based therapy by suppressing the novel prognostic factor CDCA3 in non- small cell lung cancer

Authors
  • Adams, M.
  • Burgess, J.
  • Richard, D.
  • O'Byrne, K.
Publication Date
Jan 23, 2019
Source
Queensland University of Technology ePrints Archive
Keywords
License
Unknown

Abstract

Introduction: Lung cancer is the leading cause of cancer-related mortality worldwide a survival rate of 14%. While platinum-based chemotherapy remains the most effective non-small cell lung cancer (NSCLC) treatment, less than 35% of patients have an objective partial response. Novel approaches are needed to best identify the patients who will derive the most benefit and prevent unnecessary treatment and toxicity. Herein we describe cell division cycle associated protein-3 (CDCA3) as a novel prognostic factor to delay or prevent platinum resistance in NSCLC.

Report this publication

Statistics

Seen <100 times